Alkermes reiterated by Merrill at buy

Alkermes Inc. was reiterated by Merrill Lynch analyst Hari Sambasivam at a buy rating with a price target on the stock of $19 per share following the release of the National Institute on Alcohol Abuse and Alcoholism's 2005 guide regarding alcohol dependence. Merrill believes the guide bodes well for Vivitrex, an injectable treatment for alcoholism in development by Alkermes. Alkermes shares Monday dropped $0.36, or 2.27%, to close at $15.49 on volume of 435,709 shares versus the three-month running average of 1,029,850 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.